GeoVax Labs Inc. (NASDAQ:GOVX) Short Interest Update

GeoVax Labs Inc. (NASDAQ:GOVX) was the recipient of a significant drop in short interest during the month of July. As of July 31st, there was short interest totaling 57,276 shares, a drop of 61.9% from the July 15th total of 150,485 shares. Approximately 1.7% of the shares of the company are short sold. Based on an average trading volume of 220,342 shares, the days-to-cover ratio is presently 0.3 days.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Wall Street Zen raised GeoVax Labs from a “sell” rating to a “hold” rating in a report on Sunday, June 21st. D. Boral Capital restated a “hold” rating on shares of GeoVax Labs in a research note on Thursday, April 16th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of GeoVax Labs in a research note on Friday, July 17th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, GeoVax Labs has a consensus rating of “Reduce” and a consensus price target of $150.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of GOVX. Jane Street Group LLC bought a new position in shares of GeoVax Labs in the 1st quarter valued at $27,000. Armistice Capital LLC acquired a new position in GeoVax Labs in the 3rd quarter worth about $253,000. Renaissance Technologies LLC acquired a new position in GeoVax Labs in the 4th quarter worth about $104,000. HRT Financial LP bought a new position in GeoVax Labs in the fourth quarter valued at about $31,000. Finally, Rice Hall James & Associates LLC bought a new position in GeoVax Labs in the second quarter valued at about $1,888,000. Institutional investors own 6.09% of the company’s stock.

GeoVax Labs Stock Down 1.1%

Shares of GeoVax Labs stock opened at $0.72 on Friday. The stock has a market capitalization of $2.49 million, a price-to-earnings ratio of -0.06 and a beta of 3.73. GeoVax Labs has a twelve month low of $0.64 and a twelve month high of $20.00. The company has a 50-day simple moving average of $1.05 and a two-hundred day simple moving average of $1.54.

GeoVax Labs (NASDAQ:GOVX) last issued its quarterly earnings results on Monday, July 27th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.16) by $1.19. On average, sell-side analysts anticipate that GeoVax Labs will post -4.94 earnings per share for the current fiscal year.

GeoVax Labs Company Profile

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.